New shot aims to train immune system against Hard-to-Treat breast cancer
Disease control
Recruiting now
This early-stage trial tests a new treatment called ES2B-C001, given alone or with an adjuvant, in 40 adults with HER2-positive metastatic breast cancer that has not responded to at least two prior therapies. The goal is to see if it is safe and can boost the immune system to fig…
Phase: PHASE1 • Sponsor: ExpreS2ion Biotechnologies • Aim: Disease control
Last updated May 07, 2026 18:39 UTC